INHIBITING MIR-10A OVERCOMES CYTARABINE-RESISTANCE IN ACUTE MYELOID LEUKAEMIA

被引：0
|
作者：
Vu, T. T. [1 ]
Wang, K. [1 ]
Stoelzel, F. [2 ]
Ehninger, G. [2 ]
Molloy, T. [1 ]
Ma, D. [1 ]
机构：
[1] St Vincents Hosp, Haematol, Sydney, NSW, Australia
[2] Univ Hosp Carl Gustav Carus, Med Clin & Policlin 1, Dresden, Germany
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E880
引用
收藏
页码：362 / 362
页数：1
相关论文
共 50 条
  • [31] miR signatures and the role of miRs in acute myeloid leukaemia
    Seca, Hugo
    Almeida, Gabriela M.
    Guimaraes, Jose E.
    Helena Vasconcelos, M.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (09) : 1520 - 1527
  • [32] Cross resistance to cytarabine in childhood acute myeloid leukemia
    Hubeek, I
    Peters, GJ
    Broekhuizen, AJF
    Zwaan, CM
    Van Wering, ER
    Creutzig, U
    Kaspers, GJL
    LEUKEMIA, 2003, 17 (03) : 680 - 680
  • [33] Modulation of cytarabine resistance in childhood acute myeloid leukemia
    Hubeek, I
    Peters, GJ
    Broekhuizen, AJF
    Zwaan, CM
    Creutzig, U
    Kaspers, GJL
    LEUKEMIA, 2003, 17 (03) : 681 - 681
  • [34] Problems related to resistance to cytarabine in acute myeloid leukemia
    Cros, E
    Jordheim, L
    Dumontet, C
    Galmarini, CM
    LEUKEMIA & LYMPHOMA, 2004, 45 (06) : 1123 - 1132
  • [35] Classical multidrug resistance in acute myeloid leukaemia
    Paietta, E
    MEDICAL ONCOLOGY, 1997, 14 (01) : 53 - 60
  • [36] Overcoming resistance in acute myeloid leukaemia treatment
    Isabel Lokody
    Nature Reviews Cancer, 2014, 14 : 453 - 453
  • [37] Classical multidrug resistance in acute myeloid leukaemia
    Elisabeth Paietta
    Medical Oncology, 1997, 14 : 53 - 60
  • [38] Inhibition of myeloid cell leukaemia 1 (MCL1) overcomes bromodomain and extra-terminal (BET) inhibition resistance in acute myeloid leukaemia (AML) cells
    Ladikou, E.
    Chevassut, T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 55 - 55
  • [39] Auricular Oedema and Dyshidrotic Eczema in a Patient with Acute Myeloid Leukaemia Treated with Cytarabine
    Brandt, K.
    Schaekel, K.
    Stoelzel, F.
    Janschek, J.
    Ehninger, G.
    Schaich, M.
    CASE REPORTS IN ONCOLOGY, 2010, 3 (03): : 349 - 353
  • [40] Phenotypical difference in deamination of cytarabine is not evident in induction therapy for acute myeloid leukaemia
    Krogh-Madsen, Mikkel
    Honore, Steen Hansen
    Jensen, Morten Krogh
    Nielsen, Ove Juul
    Jensen, Hannah Sondergaard
    Honore, Per Hartvig
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2013, 20 (03): : 185 - 188
12345